Results 201 to 210 of about 252,541 (298)

B cell receptor-based hybridoma enrichment enables discovery of antibodies against intracellular tumor antigens. [PDF]

Front Immunol
Dotan I, Raviv Y, Bublik DR, Kortendieck JA, Jain S, Glucksam Galnoy Y, Smorodinsky NI, Barzel A.   +7 more
europepmc   +1 more source

Independent validation of the International Metabolic Prognostic Index (CAR‐IMPI) in patients with aggressive diffuse large B‐cell lymphoma treated with CAR‐T

British Journal of Haematology, EarlyView.
Eugenio Galli, Andrea Guarneri, Alessandro Corrente, Francesca Maria Portonera, Elena Romano Gargarella, Ilaria Pansini, Patrizia Chiusolo, Federica Sorà, Maria Lucia Calcagni, Simona Sica, Stefan Hohaus, Lucia Leccisotti   +11 more
wiley   +1 more source

Bullous Eruption Associated With Loncastuximab Tesirine in a Patient With Diffuse Large B‐Cell Lymphoma

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Loncastuximab tesirine (LT) is an antibody‐drug conjugate (ADC), a novel class of therapeutics that combines a target‐specific monoclonal antibody with a cytotoxic agent via a chemical linker. LT has been approved in the United States as therapy for relapsed or refractory diffuse large B‐cell lymphoma (DLBCL).
Daniella Jaguan, Cuong Nguyen, Jennifer N. Choi   +2 more
wiley   +1 more source

Intrinsic tumor cell line immunogenicity may drive CAR-independent T cell responses and confound CAR T cell preclinical modeling. [PDF]

J Immunother Cancer
Sheng MK, Firoz WA, Loi K, Vick LV, Collins CP, Nielsen RN, Schmeling JL, Gulati S, Judge SJ, Canter RJ, Monjazeb AM, Zamora AE, Murphy WJ.   +12 more
europepmc   +1 more source

Outcomes for post‐transplant relapsed acute lymphoblastic leukaemia in the era of novel therapies: A retrospective multicentre UK study

British Journal of Haematology, EarlyView.
Alexandros Rampotas, Amy A. Kirkwood, Maximillian Brodermann, Nicola Maciocia, Fotios Panitsas, Sridhar Chaganti, Styliani Bouziana, Emma Nicholson, Samantha Drummond, Michelle Lannon, Amy Publicover, Sharon Allen, Isaac Gannon, Andrew J. King, Anne‐Louise Latif, Henry Crosland, Claire Roddie   +16 more
wiley   +1 more source

InflaMix Predicts Severe CRS, ICU Admission, and Progression‐Free Survival After CAR‐T Therapy in LBCL

European Journal of Haematology, EarlyView.
ABSTRACT Objectives Baseline systemic inflammation has emerged as a determinant of outcome after CD19‐directed CAR‐T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B‐cell lymphoma (LBCL) receiving commercial CAR‐T cells, focusing ...
Eugenio Galli, Daniele Mannina, Alessandro Corrente, Chiara De Philippis, Ilaria Pansini, Marcello Viscovo, Stefan Hohaus, Patrizia Chiusolo, Federica Sorà, Stefania Bramanti, Simona Sica   +10 more
wiley   +1 more source

Antibody-Based Therapeutics in Autoimmune Diseases: Mechanisms, Challenges, and Future Perspectives. [PDF]

Int J Mol Sci
Mahroum N.
europepmc   +1 more source

Combining TAG‐72CAR with anti‐MUC16CAR improves the potency of ovarian cancer treatment

The FEBS Journal, EarlyView.
Tz‐KBBCAR, a combinatorial CAR targeting MUC16 and TAG‐72, enhances the precision of ovarian cancer immunotherapy. By requiring both tumour antigens for full activation, Tz‐KBBCAR was designed to eliminate MUC16+/TAG‐72+ cancer cells, while sparing MUC16+/TAG‐72‐ healthy cells.
Alicia Villatoro, Aurore Dougé, Klara Krpina, Lea‐Marie Schmitz, Christopher Forcados, Fatemeh Kaveh, Andrea Estrella Arias‐Díaz, Pascal Gelebart, Emmet McCormack, Renata Stripecke, Miguel Abal, Ben Davidson, Else Marit Inderberg, Sébastien Wälchli   +13 more
wiley   +1 more source

CAR T cell therapy beyond cancer: current status, challenges and future prospects. [PDF]

Signal Transduct Target Ther
Upadhyay S, Cho S, Upmanyu K, Gabr MT.
europepmc   +1 more source